

# 2<sup>ND</sup> ESMO PROSTATE CANCER PRECEPTORSHIP ASIA

Chair: Dr Ravindran Kanesvaran  
Dr Rosa Nadal Rios



# ESMO PRECEPTORSHIP PROGRAMME PROSTATE CANCER

Multidisciplinary management, standards of care,  
therapeutic targets and future perspectives

**Singapore**  
**15-16 November 2017**

---

## CO-CHAIRS:

Ravindran Kanesvaran, Singapore

Rosa Nadal Rios, United States of America

## SPEAKERS:

Arun Azad, Australia

Melvin Lee Kiang Chua, Singapore

Jin Wei Kwek, Singapore

Lui Shiong Lee, Singapore

Lisa Pickering, United Kingdom

Bruce Hoan Tan, Singapore

# LEARNING OBJECTIVES



## LEARNING OBJECTIVES

---

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

### Wednesday, 15 November 2017

<b>09:00-09:15</b> 15'	<b>Opening and welcome</b>	
15'	Welcome from ESMO - objectives and scientific introduction	Ravindran Kanesvaran, SG Rosa Nadal Rios, US
<b>09:15-10:30</b> 75'	<b>SESSION 1</b> <b>Screening, diagnosis and staging</b>	<b>Chair:</b> <b>Puay Hoon Tan, SG</b>
20'	PSA screening and diagnosis	Lui Shiong Lee, SG
20'	Diagnosis and impact of pathology on prognosis	Puay Hoon Tan, SG
20'	Latest in imaging and staging classification	Jin Wei Kwak, SG
15'	Discussion	Faculty
<b>10:30-11:00</b>	<b>Coffee break</b>	
<b>11:00-12:30</b> 90'	<b>SESSION 2</b> <b>Localized prostate cancer</b>	<b>Chair:</b> <b>Lui Shiong Lee, SG</b>
20'	Role of radiotherapy	Melvin Lee Kiang Chua, SG
20'	Role of surgery	Lui Shiong Lee, SG
20'	Active surveillance	Rosa Nadal Rios, US
2x15'	2 x Participants clinical case discussion	Faculty
<b>12:30-13:30</b>	<b>Lunch</b>	
<b>13:30-15:15</b> 105'	<b>SESSION 3</b> <b>Advanced prostate cancer</b>	<b>Chair:</b> <b>Ravindran Kanesvaran, SG</b>
15'	Presentation with lymphadenopathy	Melvin Lee Kiang Chua, SG
20'	Value and role of PSA as a tumour marker of response/relapse	Arun Azad, AU
10'	Managing urinary obstruction	Lui Shiong Lee, SG
	<b>Debate:</b> This house believes that locally advanced prostate cancer should be treated with radiotherapy and hormone deprivation	
10'	Arguments For	Melvin Lee Kiang Chua, SG
10'	Arguments Against	Lui Shiong Lee, SG
10'	Discussion	Faculty
2x15'	2 x Participants clinical case discussion	Faculty
<b>15:15-15:45</b>	<b>Coffee break</b>	
<b>15:45-17:30</b> 105'	<b>SESSION 4</b> <b>Initial systemic therapy</b>	<b>Chair:</b> <b>Lisa Pickering, UK</b>
30'	Chemohormonal therapy in Hormone-Sensitive Prostate Cancer (HSPC)	Ravindran Kanesvaran, SG
30'	Androgen Deprivation Therapy (ADT) in HSPC: To add Abiraterone or Docetaxel?	Lisa Pickering, UK
3x15'	3 x Participants clinical case discussion	Faculty
<b>20:00</b>	<b>Dinner</b>	

### Thursday, 16 November 2017

<b>08:30-10:00</b> 90'	<b>SESSION 5</b> <b>Current treatment in Castration Resistant Prostate Cancer (CRPC)</b>	<b>Chair:</b> <b>Rosa Nadal Rios, US</b>
30'	Second-line hormone therapies and chemotherapy	Lisa Pickering, UK
30'	Chemotherapy	Arun Azad, AU
2x15'	2 x Participants clinical case discussion	Faculty
<b>10:00-10:30</b>	<b>Coffee break</b>	
<b>10:30-11:50</b> 80'	<b>SESSION 6</b> <b>CRPC: Bone modulation and the future</b>	<b>Chair:</b> <b>Arun Azad, AU</b>
20'	Bone targeting (Bisphosphonates, RANK ligands and radioisotopes)	Lisa Pickering, UK
30'	New drug targets (including PSMA targeted agents)	Arun Azad, AU
10'	Discussion: Sequencing of treatments	Faculty
2x15'	2 x Participants clinical case discussion	Faculty
<b>11:50-12:05</b> 15'	<b>Conclusion and farewell</b>	<b>Rosa Nadal Rios, US</b>
<b>12:05-13:05</b>	<b>Lunch</b>	



GOOD SCIENCE  
BETTER MEDICINE  
BEST PRACTICE

ESMO PRECEPTORSHIP  
ON PROSTATE CANCER

15-16 NOVEMBER 20  
SINGAPORE

## DEMOGRAPHIC DATA

Participants	42
Faculty	8
<b>Total</b>	<b>50</b>

### Participants Gender

Female	9	<b>21.43%</b>
Male	33	<b>78.57%</b>

Participants Average age: **34.64 years**

### Participants Country breakdown

India	
Australia	
Singapore	
Taiwan	
Indonesia	
Russian Federation	
Hong Kong	
Macau	
Malaysia	
Thailand	

**ESMO PRECEPTORSHIP ON  
PROSTATE CANCER**

**15-16 NOVEMBER 2017  
SINGAPORE**

ESMO wishes to thank the following companies for supporting this  
ESMO Preceptorship Programme

**AMGEN**<sup>®</sup>

 **astellas**